BioSpace News Archive

Verastem Oncology today reported financial results for the three months and full year ended December 31, 2021, and highlighted recent progress.

enVVeno Medical Corporation today provided a corporate update and reported financial results for the fourth quarter and year-end of 2021.

Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO).

Hangzhou Tigermed Consulting Co., Ltd. announced its annual results for the year ended December 31, 2021 (the “Reporting Period”).

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced the launch of its ready-to-use Ephedrine Sulfate Injection, a formulation pre-diluted to a 5mg/mL concentration and supplied in a 10mL vial.

Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021.

AIM ImmunoTech Inc. announced that study data evaluating the direct effects of Ampligen® on human pancreatic ductal adenocarcinoma cells was accepted for presentation at the 15th Annual International Hepato-Pancreato-Biliary Association World Congress being held March 30 – April 2, 2022 in New York, NY.

BridgeBio Pharma, Inc. announced that updated data from its ongoing Phase 2 open-label extension study of acoramidis in patients with symptomatic transthyretin amyloid cardiomyopathy will be featured in an oral presentation at the American College of Cardiology Annual Scientific Session & Expo, taking place in Washington, D.C. on April 2 – 4, 2022.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.